Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Sulfonamides Stories

2014-04-01 08:28:25

RARITAN, N.J., April 1, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a once-daily fixed-dose antiretroviral combination tablet containing darunavir, a protease inhibitor developed by Janssen R&D Ireland and marketed as PREZISTA(®) in the U.S., with cobicistat, an investigational pharmacokinetic enhancer or boosting agent, developed...

Study Finds Drug-Resistant Melanoma Treatments May Be Enhanced
2013-11-22 09:27:11

April Flowers for redOrbit.com - Your Universe Online More than 8,000 Americans are killed each year by melanoma -- the deadliest form of skin cancer. The presence of mutations in a gene known as the BRAF gene drives approximately 40 percent of advanced melanoma tumors. New medications, called BRAF inhibitors, have shown an ability to rapidly shrink melanoma tumors, however BRAF-mutated tumors often resist early treatment and only partially respond to BRAF inhibitors, which leaves...

2013-11-18 16:29:20

- Company to host webcast and conference call today at 5:00 p.m. EST - NASDAQ: CRME TSX: COM VANCOUVER and GENEVA, Nov. 18, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has completed the acquisition of Correvio LLC ("Correvio"), a privately held pharmaceutical company headquartered in Geneva, Switzerland. Key benefits of the transaction include the following: -- Accelerates Cardiome's launch of BRINAVESS(TM)...

2013-11-12 08:36:51

VIENNA, Va., Nov. 12, 2013 /PRNewswire/ -- Sarfez Pharmaceuticals has completed a trial of its novel loop diuretic drug that has the potential to revolutionize the quality of life and life expectancy of patients suffering from chronic kidney disease, congestive heart failure and resistant hypertension. By adapting an existing drug--Torsemide-- into a much-needed extended release formulation, Sarfez is hoping to give patients resistant to the current diuretics a drug that will support...

2013-11-12 08:35:17

CLEVELAND, Nov. 12, 2013 /PRNewswire/ -- ChanRx, a firm developing medicines for cardiovascular diseases, today announced that it will be presenting the results of its Phase IIb study of vanoxerine (GBR-12909), a drug under study for the treatment of atrial fibrillation, at the American Heart Association 2013 Scientific Sessions conference. The study, titled "COR-ART: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose Modification Study to Evaluate Single Oral Doses of...

2013-10-15 04:21:04

BEERSE, Belgium, October 15, 2013 /PRNewswire/ -- Janssen-Cilag International NV (Janssen), today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen, with cobicistat, a pharmacokinetic enhancer or boosting agent, developed by Gilead Sciences, Inc. (Gilead) for use in...

2013-09-16 12:28:12

LAVAL, QC, Sept. 16, 2013 /CNW/ - Actelion Pharmaceuticals Canada Inc. announced today that CARIPUL®( )(epoprostenol) for Injection is now available in Canada. CARIPUL® is a prescription medication indicated for the long-term intravenous treatment of primary pulmonary hypertension (or idiopathic pulmonary arterial hypertension), and secondary pulmonary hypertension due to scleroderma spectrum of diseases in NYHA functional Class III and Class IV patients who did not respond...

2013-09-12 20:21:33

DENVER, Sept. 12, 2013 /PRNewswire/ -- ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study. This open-label study, for the first time, compared once-daily regimens containing 50mg dolutegravir with once-daily regimens containing a protease inhibitor (PI) (800mg darunavir boosted with 100mg ritonavir) in treatment-naive adults with HIV-1. Both treatment arms were administered with investigator-selected dual NRTIs. Non-inferiority was demonstrated...

2013-06-13 04:21:45

LONDON, June 13, 2013 /PRNewswire/ -- Magicool Plus(R) range of OTC topical, Class IIa sprays were recently listed in the NHS Drug Tariff part IX, under a specially created category and is available on prescription and OTC. The range comprises Magicool Plus(R) Prickly Heat, Magicool Plus(R) Itchy Skin due to Summer Ailments and Magicool Plus(R) Sunburn, for treating mild to severe forms of the respective conditions. (Logo:...

2013-06-12 04:22:03

DUBLIN, June 12, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/3c9pm9/research_report) has announced the addition of the "Research Report on China's Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017" [http://www.researchandmarkets.com/research/3c9pm9/research_report ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Benign prostatic hyperplasia (BPH) is a common...